Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech).
Intern Med
; 62(13): 2013-2017, 2023 Jul 01.
Article
in English
| MEDLINE | ID: covidwho-2290800
ABSTRACT
A Japanese man experienced three episodes of hypovolemic shock and was diagnosed with systemic capillary leak syndrome (SCLS). He developed SCLS exacerbation 2 days after receiving a second dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine, 1 year after the third episode. After fluid therapy and albumin administration, we initiated terbutaline and theophylline prophylaxis for SCLS. A literature review revealed that SCLS attacks often occur 1-2 days after the second COVID-19 vaccination. Patients with a history of SCLS should avoid COVID-19 vaccination and be carefully monitored for 1-2 days if they receive the vaccine.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Capillary Leak Syndrome
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Prognostic study
/
Reviews
Topics:
Vaccines
Limits:
Humans
/
Male
Language:
English
Journal:
Intern Med
Journal subject:
Internal Medicine
Year:
2023
Document Type:
Article
Affiliation country:
Internalmedicine.1682-23
Similar
MEDLINE
...
LILACS
LIS